Skip header and navigation

17 records – page 1 of 1.

Price negotiations for prescription drugs

https://policybase.cma.ca/en/permalink/policy11649
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the pan-Canadian Pharmaceutical Alliance to invite the federal government and private health insurance industry to participate in its price negotiations for prescription drugs.
Policy Type
Policy resolution
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the pan-Canadian Pharmaceutical Alliance to invite the federal government and private health insurance industry to participate in its price negotiations for prescription drugs.
Less detail

National strategy on the use of naloxone

https://policybase.cma.ca/en/permalink/policy11651
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the development and implementation of a national strategy on the use of naloxone.
Policy Type
Policy resolution
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the development and implementation of a national strategy on the use of naloxone.
Less detail

Equitable and comprehensive national pharmacare program

https://policybase.cma.ca/en/permalink/policy11652
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the development of an equitable and comprehensive national pharmacare program.
Policy Type
Policy resolution
Date
2015-Aug-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the development of an equitable and comprehensive national pharmacare program.
Less detail

CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)

https://policybase.cma.ca/en/permalink/policy11599
Date
2015-Jun-08
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Complementary and alternative medicine (update 2015)

https://policybase.cma.ca/en/permalink/policy11529
Date
2015-May-30
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/en/permalink/policy11535
Date
2015-May-30
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/en/permalink/policy11519
Date
2015-May-14
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

CMA statement authorizing marijuana for medical purposes (update 2015)

https://policybase.cma.ca/en/permalink/policy11514
Date
2015-Feb-28
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Natural health products

https://policybase.cma.ca/en/permalink/policy9255
Date
2008-Aug-20
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal minister of health to prohibit claims of the therapeutic value of natural health products for the treatment of diseases listed in Schedule A of the Food and Drug Act when the supportive evidence does not meet the evidentiary standard required of medications regulated by the Health Products and Food Branch of Health Canada.
Policy Type
Policy resolution
Last Reviewed
2015-Feb-28
Date
2008-Aug-20
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal minister of health to prohibit claims of the therapeutic value of natural health products for the treatment of diseases listed in Schedule A of the Food and Drug Act when the supportive evidence does not meet the evidentiary standard required of medications regulated by the Health Products and Food Branch of Health Canada.
Less detail

Access to information regarding drug costs

https://policybase.cma.ca/en/permalink/policy9273
Date
2008-Aug-20
Topics
Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association recommends that physicians be provided with ready access to information regarding drug costs so these may be factored into decisions regarding patient care.
Policy Type
Policy resolution
Last Reviewed
2015-Feb-28
Date
2008-Aug-20
Topics
Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association recommends that physicians be provided with ready access to information regarding drug costs so these may be factored into decisions regarding patient care.
Less detail

CMA Submission to the House of Commons Standing Committee on Health - regarding Post-Market Surveillance of Pharmaceutical Products

https://policybase.cma.ca/en/permalink/policy9112
Date
2008-Feb-28
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

CMA Letter to the Senate Committee on Legal and Constitutional Affairs regarding Bill C-2, An Act to amend the Criminal Code and to make consequential amendments to other Acts

https://policybase.cma.ca/en/permalink/policy9110
Date
2008-Feb-19
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Letter on cross-border pharmacy control

https://policybase.cma.ca/en/permalink/policy1947
Date
2005-Nov-08
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Study on Mental Health, Mental Illness and Addiction in Canada : Supplementary Submission to the Senate Standing Committee on Social Affairs, Science and Technology

https://policybase.cma.ca/en/permalink/policy1945
Date
2005-Oct-11
Topics
Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Mental Health, Mental Illness & Addiction : CMA Submission to the Standing Committee on Social affairs, Science and Technology

https://policybase.cma.ca/en/permalink/policy1950
Date
2005-Apr-20
Topics
Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Adverse reactions between alcohol and drug products

https://policybase.cma.ca/en/permalink/policy805
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Less detail

Drug product substitution

https://policybase.cma.ca/en/permalink/policy806
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Less detail

17 records – page 1 of 1.